Imaging characteristics of driver mutations in EGFR, KRAS, and ALK among treatment-naïve patients with advanced lung adenocarcinoma

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Park, Jangchul ^a,b   Kobayashi, Yoshihisa ^c   Urayama, Kevin Y ^d   Yamaura, Hidekazu ^a   Yatabe, Yasushi ^a   Hida, Toyoaki ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b Nagoya City East Medical Center   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; PROTEIN TYROSINE KINASE;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EGFR GENE; EXTRANODAL INVASION; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GROUND GLASS OPACITY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG DISEASE; LUNG METASTASIS; LYMPHADENOPATHY; LYMPHANGITIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PLEURA EFFUSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; TUMOR INVASION; ADENOCARCINOMA; DIAGNOSTIC IMAGING; GENETICS; IMAGE PROCESSING; LARGE CELL CARCINOMA; LUNG TUMOR; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROCEDURES; PROGNOSIS; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE REARRANGEMENT; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84983485900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161081     Document Type: Article

References (31)

1. Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, et al. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer 2012; 118: 5840-5847. doi: 10.1002/cncr.27637 PMID: 22605530
2. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12: 175-180. doi: 10.1016/S1470-2045(10)70087-5 PMID: 21277552
3. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005; 23: 2513-2520. PMID: 15738541
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957. doi: 10.1056/NEJMoa0810699 PMID: 19692680
5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388. doi: 10.1056/NEJMoa0909530 PMID: 20573926
6. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735-742. doi: 10.1016/S1470-2045(11)70184-X PMID: 21783417
7. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16: 141-151. doi: 10.1016/S1470-2045(14)71173-8 PMID: 25589191
8. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13: 1011-1019. doi: 10.1016/S1470-2045(12)70344-3 PMID: 22954507
9. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371: 2167-2177. doi: 10.1056/NEJMoa1408440 PMID: 25470694
10. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385-2394. doi: 10.1056/NEJMoa1214886 PMID: 23724913
11. Mitsudomi T, Suda K, Yatabe Y. Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol. 2013; 10: 235-244. doi: 10.1038/nrclinonc.2013.22 PMID: 23438759
12. Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 2012; 77: 319-325. doi: 10.1016/j.lungcan.2012.03.013 PMID: 22483782
13. Park J, Yamaura H, Yatabe Y, Hosoda W, Kondo C, Shimizu J, et al. Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. Cancer Med. 2014; 3: 118-123. doi: 10.1002/cam4.172 PMID: 24403104
14. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn. 2006; 8: 335-341. PMID: 16825506
15. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722. doi: 10.1148/radiol.2462070712 PMID: 18195376
16. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27: 4247-4253. doi: 10.1200/JCO.2009.22.6993 PMID: 19667264
17. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15: 5216-5223. doi: 10.1158/1078-0432.CCR-09-0802 PMID: 19671850
18. Choi H, Paeng JC, Kim DW, Lee JK, Park CM, Kang KW, et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer 2013; 79: 242-247. doi: 10. 1016/j.lungcan.2012.11.021 PMID: 23261227
19. Halpenny DF, Riely GJ, Hayes S, Yu H, Zheng J, Moskowitz CS, et al. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? Lung Cancer 2014; 86: 190-194. doi: 10.1016/j.lungcan.2014.09.007 PMID: 25312988
20. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012; 118: 4502-4511. doi: 10.1002/cncr.27409 PMID: 22282022
21. Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, et al. A dramatic response to crizotinib in a nonsmall-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol. 2012; 7: e36-38. doi: 10.1097/JTO.0b013e318274694e PMID: 23154564
22. Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, et al. Atypical negative ALK breakapart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol. 2014; 9: e21-23. doi: 10.1097/JTO.0000000000000013 PMID: 24518095
23. Yano M, Sasaki H, Kobayashi Y, Yukiue H, Haneda H, Suzuki E, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol. 2006; 1: 413-416. PMID: 17409892
24. Blons H, Cote JF, Le Corre D, Riquet M, Fabre-Guilevin E, Laurent-Puig P, et al. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol. 2006; 30: 1309-1315. PMID: 17001163
25. Sabri A, Batool M, Xu Z, Bethune D, Abdolell M, Manos D, et al. Predicting EGFR mutation status in lung cancer: Proposal for a scoring model using imaging and demographic characteristics. Eur Radiol. 2016 Mar 30. In press.
26. Hsu JS, Huang MS, Chen CY, Liu GC, Liu TC, Chong IW, et al. Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. J Thorac Imaging 2014; 29: 357-363. doi: 10.1097/RTI.0000000000000116 PMID: 25303964
27. Laack E, Simon R, Regier M, Andritzky B, Tennstedt P, Habermann C, et al. Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. J Thorac Oncol. 2011; 6: 199-202. doi: 10.1097/JTO.0b013e3181fb7cf1 PMID: 21178715
28. Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014; 9: 195-199. doi: 10.1097/JTO.0000000000000069 PMID: 24419416
29. Enomoto Y, Takada K, Hagiwara E, Kojima E. Distinct features of distant metastasis and lymph node stage in lung adenocarcinoma patients with epidermal growth factor receptor gene mutations. Respir Investig. 2013; 51: 153-157. doi: 10.1016/j.resinv.2013.02.004 PMID: 23978641
30. Colen R, Foster I, Gatenby R, Giger ME, Gillies R, Gutman D, et al. NCI workshop report: clinical and computational requirements for correlating imaging phenotypes with genomics signatures. Transl Oncol. 2014; 7: 556-569. doi: 10.1016/j.tranon.2014.07.007 PMID: 25389451
31. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014; 5: 4006. doi: 10.1038/ncomms5006 PMID: 24892406